🇺🇸 FDA
Pipeline program

AZD6793, AZD6793 Placebo, AZD6793, AZD6793

D7860C00006

Phase 2 small_molecule active

Quick answer

AZD6793, AZD6793 Placebo, AZD6793, AZD6793 for Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials